

NOTICE OF PUBLIC HEARING

Notice is hereby given that a public hearing will be conducted telephonically by the Massachusetts Development Finance Agency (the “MassDevelopment”) at 10: 30 a.m. on Friday, April 10, 2026. The purpose of the hearing will be for MassDevelopment to consider the proposed issuance of its revenue bonds in one or more series as part of a plan of finance (the “Bonds”) for the benefit of Dana-Farber Cancer Institute, Inc. and Dana-Farber, Inc. (together, the “Institution”) to finance and refinance certain capital facilities and assets for health care purposes (collectively, the “Project”), all of which are and will be owned by the Institution and located or to be located in Massachusetts as follows:

1. Refinancing all or a portion of Massachusetts Health and Educational Facilities Authority (“MassHEFA”) Variable Rate Revenue Bonds, Dana-Farber Cancer Institute Issue, Series L-1 (2008) (the “Series L-1 Bonds”), which (I) refinanced (i) MassHEFA Revenue Bonds, Capital Asset Program Issue, Series J-1 (“Series J-1”), which financed (A) for Dana-Farber Cancer Institute, Inc., the acquisition and installation of equipment and other property and renovations and improvements of existing property to be used in connection with its patient care, research and fundraising activities and administrative, general and plant services at facilities owned or leased by the Institution, at 35, 44 and 50 Binney Street, Boston, 65 Deaconess Road, Boston, 440, 454 and 462 Brookline Avenue, Boston, 303 Boylston Street, Boston, 350 and 375 Longwood Avenue, Boston, 383 D Street, South Boston, 21-27 Burlington Avenue, Boston, 20 Overland Street, Boston, One Harvard Street, Brookline, 1309 Beacon Street, Brookline, and 10 Brookline Place, Brookline; and (B) for Dana-Farber Inc., the acquisition and installation of equipment and other property and renovations and improvements of existing property to be used in connection with its fundraising activities and administrative, general and plant services, to be located at facilities owned or leased by Dana-Farber Inc., at 35, 44 and 50 Binney Street, Boston, 65 Deaconess Road, Boston, 440, 454 and 462 Brookline Avenue, Boston, 303 Boylston Street, Boston, 350 and 375 Longwood Avenue, Boston, 383 D Street, South Boston, 21-27 Burlington Avenue, Boston, 20 Overland Street, Boston, One Harvard Street, Brookline, 1309 Beacon Street, Brookline and 10 Brookline Place, Brookline; (ii) MassHEFA Revenue Bonds, Capital Asset Program Issue, Series J-2 (“Series J-2”), which financed (A) the acquisition of 2 Gamma Cameras, a CT Scan, a Linear Accelerator and associated renovations and miscellaneous clinical equipment; and (B) the acquisition of various movable equipment, located at facilities owned or leased by the Institution at 35, 44 and 50 Binney Street, Boston, 65 Deaconess Road, Boston, 440, 454 and 462 Brookline Avenue, Boston, 303 Boylston Street, Boston, 350 and 375 Longwood Avenue, Boston, 383 D Street, South Boston, 21-27 Burlington Avenue, Boston, 20 Overland Street, Boston, One Harvard Street, Brookline, 1309 Beacon Street, Brookline and 10 Brookline Place, Brookline; (iii) MassHEFA Revenue Bonds, Capital Asset Program Issue, Series M-2, Pool 2 (“Series M-2”), which (A) refunded the Massachusetts Health and Educational Facilities Authority Variable Rate Demand Revenue Bonds, Dana-Farber Cancer Institute Issue, Series C, Series D and Series E, which refinanced a mortgage loan secured by a mortgage on the Jimmy Fund Building, which financed renovations on such building, an approximately

16,645 square foot building located at 35 Binney Street, Boston; and (B) financed the construction of a new research building on a parcel of land of approximately 8,400 square foot fronting on Brookline Avenue on the north side of the Institution's Dana Building located at 44 Binney Street, Boston; and (iv) MassHEFA Revenue Bonds, Dana-Farber Cancer Institute Issue, Periodic Auction Reset Securities (PARS), Series I-1 (2007) and Series I-1 (2007) (together, "Series I"), which financed (A) the demolition of a single-story building known as the Michael A. Redstone Laboratories located at 462 Brookline Avenue, Boston, and a two-story building located at 454 Brookline Avenue, Boston; (B) the construction, furnishing and equipping of a new 14-floor outpatient health care facility totaling approximately 275,000 square feet located at 450 Brookline Avenue, and an associated, approximately 450-car, seven-level below-ground parking structure and connector to the Institution's existing facilities; and (C) the acquisition and installation of capital equipment and furnishings and construction of improvements and renovations to existing facilities of the Institution and other routine capital expenditures, located on the Institution's main campus bounded by Brookline Avenue, Longwood Avenue, Binney Street, Shattuck Street and Francis Street, Boston, and at satellite offices and facilities located at 20 Overland Street, Boston, 27 Dry Dock Avenue, Boston, 3 Blackfan Circle, Boston, Ten Brookline Place, Brookline, 1153 Center Street, Jamaica Plain, and 14 Prospect Street, Milford; and (II) financed the costs of issuance and other common costs of the Series L-1 Bonds;

2. Refinancing all or a portion of MassDevelopment's Revenue Bonds, Dana-Farber Cancer Institute Issue, Series N (2016) (the "Series N Bonds"), which financed (i) the acquisition and fit-out of an approximately 203,000 rentable square feet of condominium and fit-out of approximately 51,000 rentable square feet of leased premises at the Longwood Center, which is used for biomedical research, and the relocation to such premises of the Institution's existing vivarium; (ii) the renovation and upgrade of HVAC systems; (iii) the relocation to, reconstruction and equipping of an approximately 31,000 rentable square feet Cell Manipulation Core Facility at the Smith Building located at One Jimmy Fund Way, Boston; (iv) routine capital expenditures; and (v) the payment of a portion of the costs of issuing the Series N Bonds;
3. Refinancing all or a portion of MassDevelopment's Revenue Bonds, Dana-Farber Cancer Institute Issue, Series P-1 (2021) and Series P-2 (2021), which refinanced MassHEFA's Variable Rate Revenue Bonds, Dana-Farber Cancer Institute Issue, Series L-2A (2008) and Series L-2B (2008), which financed (i) the refinancing of Series I, which financed (A) the demolition of a single-story building known as the Michael A. Redstone Laboratories located at 462 Brookline Avenue, Boston, and a two-story building located at 454 Brookline Avenue, Boston; (B) the construction, furnishing and equipping of a new 14-floor outpatient health care facility totaling approximately 275,000 square feet located at 450 Brookline Avenue, and an associated, approximately 450-car, seven-level below-ground parking structure and connector to the Institution's existing facilities; and (C) the acquisition and installation of capital equipment and furnishings and construction of improvements and renovations to existing facilities of the Institution and other routine capital expenditures, located on the Institution's main campus bounded by Brookline Avenue, Longwood Avenue, Binney Street, Shattuck Street and Francis Street, Boston, and at satellite offices and facilities located at 20 Overland Street, Boston, 27 Dry Dock Avenue, Boston, 3 Blackfan Circle, Boston, Ten Brookline Place, Brookline, 1153 Center

Street, Jamaica Plain, and 14 Prospect Street, Milford; (ii) the refinancing of Series J-1, which financed (A) for Dana-Farber Cancer Institute, Inc., the acquisition and installation of equipment and other property and renovations and improvements of existing property to be used in connection with its patient care, research and fundraising activities and administrative, general and plant services at facilities owned or leased by the Institution, at 35, 44 and 50 Binney Street, Boston, 65 Deaconess Road, Boston, 440, 454 and 462 Brookline Avenue, Boston, 303 Boylston Street, Boston, 350 and 375 Longwood Avenue, Boston, 383 D Street, South Boston, 21-27 Burlington Avenue, Boston, 20 Overland Street, Boston, One Harvard Street, Brookline, 1309 Beacon Street, Brookline, and 10 Brookline Place, Brookline; and (B) for Dana-Farber Inc., the acquisition and installation of equipment and other property and renovations and improvements of existing property to be used in connection with its fundraising activities and administrative, general and plant services, to be located at facilities owned or leased by Dana-Farber Inc., at 35, 44 and 50 Binney Street, Boston, 65 Deaconess Road, Boston, 440, 454 and 462 Brookline Avenue, Boston, 303 Boylston Street, Boston, 350 and 375 Longwood Avenue, Boston, 383 D Street, South Boston, 21-27 Burlington Avenue, Boston, 20 Overland Street, Boston, One Harvard Street, Brookline, 1309 Beacon Street, Brookline and 10 Brookline Place, Brookline; (iii) the refinancing of Series J-2, which financed (A) the acquisition of 2 Gamma Cameras, a CT Scan, a Linear Accelerator and associated renovations and miscellaneous clinical equipment; and (B) the acquisition of various movable equipment, located at facilities owned or leased by the Institution at 35, 44 and 50 Binney Street, Boston, 65 Deaconess Road, Boston, 440, 454 and 462 Brookline Avenue, Boston, 303 Boylston Street, Boston, 350 and 375 Longwood Avenue, Boston, 383 D Street, South Boston, 21-27 Burlington Avenue, Boston, 20 Overland Street, Boston, One Harvard Street, Brookline, 1309 Beacon Street, Brookline and 10 Brookline Place, Brookline; and (iv) the refinancing of Series M-2, which (A) refunded the Massachusetts Health and Educational Facilities Authority Variable Rate Demand Revenue Bonds, Dana-Farber Cancer Institute Issue, Series C, Series D and Series E, which refinanced a mortgage loan secured by a mortgage on the Jimmy Fund Building, which financed renovations on such building, an approximately 16,645 square foot building located at 35 Binney Street, Boston; and (B) financed the construction of a new research building on a parcel of land of approximately 8,400 square foot fronting on Brookline Avenue on the north side of the Institution's Dana Building located at 44 Binney Street, Boston.

All of the foregoing refinanced projects are used by the Institution in an integrated operation to provide health care services to the populations served by the Institution. The Bonds will be issued to refinance the Series L-1 Bonds, the Series N Bonds and the Series P Bonds in an aggregate stated principal amount not exceeding \$475,000,000.

4. Financing the cost of acquisition, construction, expansion, remodeling, renovation, furnishing, and equipping (including through the acquisition and/or implementation of electronic medical record and other information systems) of the health and related facilities owned and operated, or to be owned and operated, by the Institution in an integrated operation to provide health care services to the populations served by the Institution (in each case using the Bonds in an aggregate principal amount not exceeding \$1,500,000,000) at the following locations or adjacent or proximate sites: One Joslin Place, Boston, 33 Binney Street, Boston, 43-44 Binney Street, Boston, 50 Binney Street, Boston, 1290 Tremont Street, Boston, 165 Allandale Road, Boston, 20 Overland Street,

Boston, 21-27 Burlington Avenue, Boston, 27 Drydock Avenue, Boston, 3-4 Blackfan Circle, Boston, 360 Longwood Avenue, Boston, 375 Longwood Avenue, Boston, 50 Industrial Drive, Boston, 75 Francis Street, Boston, Brookline Avenue, Boston, 330 Brookline Avenue, Boston, 400 Brookline Avenue, Boston, 440 Brookline Avenue, Boston, 1 Jimmy Fund Way, Boston, 60 Guest Street, Allston, 736 Cambridge Street, Brighton, 211 Park Street, Attleboro, 10 Brookline Place, Brookline, One Patriot Place, Foxborough, 5 Branch Street, Methuen, 70 East Street, Methuen, 20 Prospect Street, Milford, 85 South Avenue, Natick, 300 Boylston Street, Newton, 51 Performance Drive, South Weymouth, and 101 Columbian Street, South Weymouth.

The proceeds of the Bonds may also be used to fund a swap termination payment, capitalized interest, costs of issuance and other common costs of the Bonds.

The plan of finance proposal includes the financing and refinancing of the costs of the Project through the issuance by MassDevelopment, acting under and pursuant to Massachusetts General Laws, Chapters 23G and 40D, of the Bonds in one or more series as “qualified 501(c)(3) bonds” under Section 145 of the Internal Revenue Code of 1986 in an aggregate principal amount not to exceed \$1,500,000,000, which Bonds will not constitute a debt or pledge of the faith and credit of MassDevelopment or of The Commonwealth of Massachusetts.

Subject to the provisions set forth below, interested persons wishing to express their views on the Project and the proposed issuance of the Bonds to finance and refinance the Project, and to fund the costs of issuance and other common costs of the Bonds, will be given the opportunity to access the public hearing by teleconference using the toll-free telephone number and participant code set forth below or may, prior to the time of the public hearing, submit their views by email to tefrahearinginfo@MassDevelopment.com or by writing to MassDevelopment at 99 High Street, Boston, Massachusetts 02110, Attention: TEFRA Hearings.

Persons wishing to participate in the hearing may use the toll-free telephone number and passcode listed below:

Dial in: 1-888-305-1655
Participant Code: 272-350

MassDevelopment expects to conduct the hearing at the date and time set forth via teleconference *only*, using the telephone number listed above.

MASSACHUSETTS DEVELOPMENT
FINANCE AGENCY